uniQure N.V. splits its revenue into 6 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was License at $15.9 million, 99% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
20
|
16
|
27
|
16
|
106
|
524
|
38
|
7
|
11
|
13
|
25
|
| License Revenue From Related Party |
—
|
—
|
—
|
—
|
—
|
—
|
33
+560.9%
share 87.9%
|
5
-33.7%
share 68.5%
|
8
+82.7%
share 66.7%
|
4
share 31.4%
|
—
|
| License |
—
|
16
+57.2%
share 99.0%
|
10
+267.4%
share 37.4%
|
3
-97.2%
share 17.4%
|
100
-80.7%
share 93.9%
|
517
+11788.8%
share 98.7%
|
4
share 11.6%
|
—
|
—
|
0
share 0.1%
|
—
|
| Contract Manufacturing Revenue |
—
|
—
|
6
-43.6%
share 22.5%
|
11
+531.0%
share 68.4%
|
2
share 1.6%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Collaborative Revenue Including Revenue From Related Party |
—
|
—
|
—
|
—
|
—
|
4
share 0.8%
|
—
|
2
share 31.6%
|
—
|
—
|
—
|
| Collaborative Revenue |
—
|
0
-98.5%
share 1.0%
|
11
+383.2%
share 40.1%
|
2
-52.8%
share 14.2%
|
5
-27.8%
share 4.5%
|
7
+11089.8%
share 1.3%
|
0
share 0.2%
|
—
|
—
|
5
share 35.4%
|
—
|
| Collaborative Revenue From Related Party |
—
|
—
|
—
|
—
|
—
|
—
|
0
-94.1%
share 0.4%
|
2
-39.0%
share 31.5%
|
4
-13.5%
share 33.3%
|
4
share 33.1%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- QURE (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Amsterdam
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1590560
- Former names
- uniQure B.V. (until Feb 6, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.